Conway, Jake R. http://orcid.org/0000-0002-6617-2054
Dietlein, Felix
Taylor-Weiner, Amaro
AlDubayan, Saud
Vokes, Natalie http://orcid.org/0000-0002-3766-5335
Keenan, Tanya
Reardon, Brendan
He, Meng Xiao
Margolis, Claire A.
Weirather, Jason L. http://orcid.org/0000-0003-0556-0616
Haq, Rizwan http://orcid.org/0000-0002-1290-9276
Schilling, Bastian http://orcid.org/0000-0001-8859-4103
Stephen Hodi, F.
Schadendorf, Dirk http://orcid.org/0000-0003-3524-7858
Liu, David
Van Allen, Eliezer M. http://orcid.org/0000-0002-0201-4444
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (Damon Runyon Clinical Investigator Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA242861, R01CA227388-02, F31CA239347)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Amazon Web Services (AWS Cloud Credits for Research Program)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5T32HG002295-15)
Claudia Adams Barr Program for Innovative Cancer Research
Article History
Received: 30 July 2020
Accepted: 14 October 2020
First Online: 23 November 2020
Competing interests
: E.M.V.A. is a consultant for Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Monte Rosa Therapeutics, Manifold Bio and Janssen, provides research support to Novartis and Bristol-Myers Squibb, has equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Monte Rosa Therapeutics and Microsoft, receives travel reimbursement from Roche/Genentech, and has institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation.